Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
peptides
Biotech
Theratechnologies halts lead cancer trial over efficacy concerns
Theratechnologies has pumped the brakes on a phase 1 trial of its lead cancer asset after a glimpse at the data raised efficacy concerns.
James Waldron
Dec 2, 2022 5:35am
Windtree sheds weight, enters near $80M biobucks deal
Aug 23, 2022 11:54am
Crinetics creates Radionetics with $30M for 10 cancer candidates
Oct 18, 2021 4:14pm
Gubra, Bayer ink $253M biobucks deal for heart, kidney collab
Sep 20, 2021 10:50am
PeptiDream signs licensing deal with Alnylam worth up to $2.2B
Jul 30, 2021 10:05am
Takeda's CNS deep dive with PeptiDream could net $3.5B
Jul 28, 2021 10:41am
